RT Journal Article
SR Electronic
T1 Sequence Proven Reinfections with SARS-CoV-2 at a Large Academic Center
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.17.22275210
DO 10.1101/2022.05.17.22275210
A1 Morris, C. Paul
A1 Eldesouki, Raghda E.
A1 Fall, Amary
A1 Gaston, David C.
A1 Norton, Julie M.
A1 Gallagher, Nicholas
A1 Luo, Chun Huai
A1 Abdullah, Omar
A1 Klein, Eili Y.
A1 Mostafa, Heba H.
YR 2022
UL http://medrxiv.org/content/early/2022/05/19/2022.05.17.22275210.abstract
AB Background Increased reinfection rates with SARS-CoV-2 have recently been reported, with some locations basing reinfection on a second positive PCR test at least 90 days after initial infection.Methods We identified cases where patients had two positive tests for SARS-CoV-2 and evaluated which of these had been sequenced as part of our surveillance efforts, and evaluated sequencing and clinical data.Results 750 patients (920 samples) had a positive test at least 90 days after the initial test. The median time between tests was 377 days, and 724 (79%) of the post 90-day positives were collected after the emergence of the Omicron variant in November 2021. Sequencing was attempted on 231 samples and successful in 127. Successful sequencing spiked during the Omicron surge and showed higher median days from initial infection compared to failed sequences (median 398 days compared to 276 days, p<0.0005). A total of 122 (98%) patients showed evidence of reinfection, 45 of which had sequence proven reinfection and 77 had inferred reinfections (later sequence showed a clade that was not circulating when the patient was initially infected). Children accounted for only 4% of reinfections. 43 (96%) of 45 infections with sequence proven reinfection were caused by the Omicron variant, 41 (91%) were symptomatic, 32 (71%), were vaccinated prior to the second infection, and 6 (13%) were Immunosuppressed. Only 2 (4%) were hospitalized, and both had underlying conditions.Conclusion Sequence proven reinfections increased with the Omicron variant but generally caused mild infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Johns Hopkins Center of Excellence in Influenza Research and Surveillance (HHSN272201400007C), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1 AI068613), the NIH RADx-Tech program (3U54HL143541-02S2), National Institute of Health RADx-UP initiative (Grant R01 DA045556-04S1), Centers for Disease Control (contract 75D30121C11061), the Johns Hopkins University President's Fund Research Response, the Johns Hopkins department of Pathology, and the Maryland department of health. EK was supported by Centers for Disease Control and Prevention (CDC) MInD-Healthcare Program (Grant Number U01CK000589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research was conducted under Johns Hopkins IRB protocol IRB00221396 with a waiver of consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomes are submitted to GISAID.